Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS)

Journal of Comparative Effectiveness Research

Volumn 4, Issue 1, 2015, Pages 3-9

  Chen, Ronald C ^a,b   Carpenter, William R ^a,c   Kim, Mimi ^a   Hendrix, Laura H ^a,b   Agans, Robert P ^a   Meyer, Anne Marie ^a,c   Hoffmeyer, Anna ^a   Reeve, Bryce B ^a,c   Nielsen, Matthew E ^a,b   Usinger, Deborah S ^a   Strigo, Tara S ^a   Jackman, Anne M ^a   Anderson, Mary ^d   Godley, Paul A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d Prostate Cancer Coalition of North Carolina   (United States)

Author keywords

brachytherapy; comparative effectiveness research; prostate cancer; prostatectomy; radiation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FOLLOW UP; GLEASON SCORE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NORTH CAROLINA PROSTATE CANCER COMPARATIVE EFFECTIVENESS AND SURVIVORSHIP STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; CANCER GRADING; DEMOGRAPHY; EPIDEMIOLOGY; METHODOLOGY; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; REGISTER; SURVIVOR; TREATMENT OUTCOME; UNITED STATES;

AGED; COMPARATIVE EFFECTIVENESS RESEARCH; DEMOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; NORTH CAROLINA; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REGISTRIES; RESEARCH DESIGN; SURVIVORS; TREATMENT OUTCOME;

EID: 84920854487     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.14.67     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
2. Siegel R, Desantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241 (2012).
3. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J. Clin. Oncol. 27, 3916-3922 (2009).
4. Resnick MJ, Koyama T, Fan KH et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 368, 436-445 (2013).
5. Sheets NC, Goldin GH, Meyer AM et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307, 1611-1620 (2012).
6. Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin. Radiat. Oncol. 23, 182-190 (2013).
7. Hu JC, Gu X, Lipsitz SR et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302, 1557-1564 (2009).
8. Nguyen PL, Gu X, Lipsitz SR et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 29, 1517-1524 (2011).
9. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. The National Academies Press, Washington, DC, USA (2009).
10. Greenberg C, Wind J, Chang G et al. Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium. J. Comp. Eff. Res. 2(2), 117-125 (2013).
11. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med. Care 39, 1118-1130 (2001).
12. Roth AJ, Rosenfeld B, Kornblith AB et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97, 2910-2918 (2003).
13. Wilt TJ. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. J. Natl Cancer Inst. Monogr. 2012(45), 184-190 (2012).
14. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203-213 (2012).
15. Lane JA, Donovan JL, Davis M et al. Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised Phase 3 trial. Lancet Oncol. 15(10), 1109-1118 (2014).
16. Concato J. Is it time for medicine-based evidence? JAMA 307, 1641-1643 (2012).
17. Potosky AL, Harlan LC, Stanford JL et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst. 91, 1719-1724 (1999).
18. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261 (2008).
19. Stokes WA, Hendrix LH, Royce TJ et al. Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study. Cancer 119, 2486-2493 (2013).